Hepion Pharmaceuticals, Inc.
HEPA
$0.2975
$0.01294.53%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.50M | 7.48M | 7.93M | 8.85M | 9.62M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.35M | 25.36M | 31.57M | 37.23M | 45.26M |
| Operating Income | -19.35M | -25.36M | -31.57M | -37.23M | -45.26M |
| Income Before Tax | -16.16M | -26.08M | -31.74M | -41.90M | -49.34M |
| Income Tax Expenses | -2.97M | -3.38M | -3.38M | -3.38M | -409.00K |
| Earnings from Continuing Operations | -13.19 | -22.70 | -28.37 | -38.52 | -48.93 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.19M | -22.70M | -28.37M | -38.52M | -48.93M |
| EBIT | -19.35M | -25.36M | -31.57M | -37.23M | -45.26M |
| EBITDA | -19.32M | -25.32M | -31.51M | -37.15M | -45.19M |
| EPS Basic | -109.29 | -223.67 | -324.59 | -474.72 | -620.54 |
| Normalized Basic EPS | -128.02 | -167.48 | -231.38 | -301.53 | -362.08 |
| EPS Diluted | -109.29 | -223.67 | -324.59 | -474.72 | -620.54 |
| Normalized Diluted EPS | -128.02 | -167.48 | -231.38 | -301.53 | -362.08 |
| Average Basic Shares Outstanding | 491.20K | 440.00K | 382.40K | 342.90K | 317.60K |
| Average Diluted Shares Outstanding | 491.20K | 440.00K | 382.40K | 342.90K | 317.60K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |